Biomaterials for vaccine-based cancer immunotherapy

The development of therapeutic cancer vaccines as a means to generate immune reactivity against tumors has been explored since the early discovery of tumor-specific antigens by Georg Klein in the 1960s. However, challenges including weak immunogenicity, systemic toxicity, and off-target effects of c...

Full description

Saved in:
Bibliographic Details
Published in:Journal of controlled release 2018-12, Vol.292, p.256-276
Main Authors: Zhang, Rui, Billingsley, Margaret M., Mitchell, Michael J.
Format: Article
Language:English
Subjects:
Animals
Biocompatible Materials
Biomaterials
Cancer vaccine
Cancer Vaccines
Humans
Immunotherapy
Lymph Nodes - metabolism
Nanomedicine
Neoplasms - therapy
Nucleic acid delivery
Personalized therapy
Precision Medicine
Targeted delivery
Translational research
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The development of therapeutic cancer vaccines as a means to generate immune reactivity against tumors has been explored since the early discovery of tumor-specific antigens by Georg Klein in the 1960s. However, challenges including weak immunogenicity, systemic toxicity, and off-target effects of cancer vaccines remain as barriers to their broad clinical translation. Advances in the design and implementation of biomaterials are now enabling enhanced efficacy and reduced toxicity of cancer vaccines by controlling the presentation and release of vaccine components to immune cells and their microenvironment. Here, we discuss the rational design and clinical status of several classes of cancer vaccines (including DNA, mRNA, peptide/protein, and cell-based vaccines) along with novel biomaterial-based delivery technologies that improve their safety and efficacy. Further, strategies for designing new platforms for personalized cancer vaccines are also considered. [Display omitted] •Cancer vaccines aim to reprogram a patient’s own immune cells to target and kill cancer cells.•Barriers to the broad clinical translation of cancer vaccines include weak immunogenicity and systemic toxicity.•Advances in biomaterials for drug delivery can overcome the challenges faced in cancer vaccination.•Nanoparticle- and implantable scaffold-based delivery technologies can improve cancer vaccine safety and efficacy.•Biomaterials for drug delivery can be exploited in future research to design platforms for personalized cancer vaccines.
ISSN:0168-3659
1873-4995
DOI:10.1016/j.jconrel.2018.10.008